Market revenue in 2023 | USD 286.5 million |
Market revenue in 2030 | USD 449.7 million |
Growth rate | 6.7% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 65.69% in 2023. Horizon Databook has segmented the Spain blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The Spanish Network of Cancer Registries (REDECAN) and Spanish Society of Hematology and Hemotherapy (SEHH) reports 19,900 new cases of lymphoid neoplasms likely to be diagnosed in 2024 in Spain, with leukemia accounting for around 20% of these cases. According to the Global Cancer Observatory (GCO), there were 5,976 new cases of leukemia diagnosed in Spain in 2022.
This trend in leukemia mortality and incidence rates is expected to drive the market for blood cancer diagnostics and treatments in Spain. The need for more effective diagnostic tools and personalized treatment options to address the rising cases and mortality rates, especially among older adults, may increase innovation & investment in the field.
For instance, in May 2022, BD acquired Cytognos, a Spanish provider of innovative flow cytometry solutions. The company's expertise in diagnosing blood cancers, detecting Minimal Residual Disease (MRD), and researching immune monitoring for blood diseases has enhanced BD's offerings in blood cancer diagnostics, immune assessment tests, & informatics.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Spain blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account